Core Viewpoint - The article highlights the strong performance of overseas stock indices and the corresponding success of QDII funds, particularly those investing in the Hong Kong and US markets, with a focus on healthcare and technology sectors [3][4][8]. Group 1: Overseas Stock Market Performance - Multiple overseas stock indices, including NASDAQ, S&P 500, and DAX, reached historical highs in July 2025, with many indices showing over 20% gains in the first half of the year [3][4]. - The DAX index recorded a 31.12% increase over the past year and an 87.03% increase over three years, while the NASDAQ and S&P 500 also showed significant gains [5][6]. Group 2: QDII Fund Overview - QDII funds, which allow domestic investors to invest in overseas markets, primarily target Hong Kong and the US, with some exposure to emerging markets like Vietnam and India [7][8]. - As of June 30, 2025, there were 525 equity QDII funds, accounting for 77.43% of total QDII funds, with a total scale of approximately 682.8 billion yuan [8]. Group 3: QDII Fund Performance - The average return for equity QDII funds in the first half of 2025 was approximately 13.46%, with a median return of 9.72%. Over three years, the average return was about 36.21% [9][10]. - The top 20 equity QDII funds in the first half of 2025 had a return threshold close to 32%, outperforming major global indices, with a significant portion invested in Hong Kong's innovative pharmaceutical sector [10][11]. Group 4: Top Performing QDII Funds - The top three performing QDII funds for the first half of 2025 were: 1. Huatai-PineBridge Hong Kong Advantage Selection Mixed (QDII) A 2. E Fund Global Pharmaceutical Industry Mixed (QDII) A 3. ICBC New Economy Mixed (QDII) RMB [11][18]. - The Huatai-PineBridge fund achieved a return of approximately 86.48% in the first half of 2025, with a one-year return of 92.59% [14][19]. Group 5: Sector Focus - The article emphasizes that a significant number of top-performing QDII funds are heavily invested in the healthcare sector, particularly in innovative pharmaceutical companies listed in Hong Kong [15][22]. - The top-performing funds over the past year also included those with substantial holdings in technology giants and new consumer companies [22][28].
海外股市又在新高,这些权益类QDII基金赢麻了!上半年20强均跑赢全球主要股指!
私募排排网·2025-07-17 03:10